{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:13:17Z","timestamp":1778847197513,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370087"],"award-info":[{"award-number":["81370087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-1-I2M-1-054"],"award-info":[{"award-number":["2021-1-I2M-1-054"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-070"],"award-info":[{"award-number":["2021-I2M-1-070"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2020-I2M-2-010"],"award-info":[{"award-number":["2020-I2M-2-010"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-2-006"],"award-info":[{"award-number":["2023-I2M-2-006"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008549","name":"Shanxi Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.apsb.2025.06.029","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:44:50Z","timestamp":1751431490000},"page":"4829-4843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Yeast-two-hybrid based high-throughput screening to discover SARS-CoV-2 fusion inhibitors by targeting the HR1\/HR2 interaction"],"prefix":"10.1016","volume":"15","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoqing","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjie","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tin Mong","family":"Timothy Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Yi","family":"Tsun Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-6388","authenticated-orcid":false,"given":"Peng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyi","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.06.029_bib1","article-title":"Role of COVID-19 vaccines in SARS-CoV-2 variants","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.06.029_bib2","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1080\/07391102.2020.1754293","article-title":"A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin","volume":"39","author":"Hasan","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.apsb.2025.06.029_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.06.029_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.virol.2006.02.003","article-title":"Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry","volume":"350","author":"Follis","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.apsb.2025.06.029_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1073","article-title":"Furin-mediated protein processing in infectious diseases and cancer","volume":"8","author":"Braun","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.apsb.2025.06.029_bib6","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1039\/D2RA07356K","article-title":"Dimerized fusion inhibitor peptides targeting the HR1\u2013HR2 interaction of SARS-CoV-2","volume":"13","author":"Tsuji","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2025.06.029_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"Xiao","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.029_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/v4020280","article-title":"Henipavirus mediated membrane fusion, virus entry and targeted therapeutics","volume":"4","author":"Steffen","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.029_bib9","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1021\/acsinfecdis.0c00915","article-title":"Discovery of a potent and selective chikungunya virus envelope protein inhibitor through computer-aided drug design","volume":"7","author":"Battini","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.029_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41579-023-01003-z","article-title":"SARS-CoV-2 biology and host interactions","volume":"22","author":"Steiner","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2025.06.029_bib11","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.apsb.2025.06.029_bib12","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.2174\/0109298673265694231113061842","article-title":"Structure and function of the SARS-CoV-2 6-HB fusion core and peptide-based fusion inhibitors: a review","volume":"32","author":"Liang","year":"2023","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2025.06.029_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.06.029_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2025.06.029_bib15","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms21165707","article-title":"SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells","volume":"21","author":"Cannalire","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.029_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2244084","article-title":"An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen","volume":"12","author":"Wang","year":"2023","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.apsb.2025.06.029_bib17","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.apsb.2023.05.030","article-title":"HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration","volume":"13","author":"Lu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.029_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01935-20","article-title":"Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 spike glycoprotein HRC domain","volume":"11","author":"Outlaw","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.06.029_bib19","article-title":"Drug repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by blocking SARS-CoV-2 spike protein-mediated membrane fusion","volume":"4","author":"Yang","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2025.06.029_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170328","article-title":"In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2","volume":"130","author":"Ling","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.06.029_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105362","article-title":"A robust high-throughput fluorescent polarization assay for the evaluation and screening of SARS-CoV-2 fusion inhibitors","volume":"116","author":"Yin","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2025.06.029_bib22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/v14061295","article-title":"Borneol ester derivatives as entry inhibitors of a wide spectrum of SARS-CoV-2 viruses","volume":"14","author":"Yarovaya","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.029_bib23","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.ijbiomac.2022.10.031","article-title":"Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity","volume":"222","author":"Cano-Munoz","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2025.06.029_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710067","article-title":"Targeting the SARS-CoV-2 HR1 with small molecules as inhibitors of the fusion process","volume":"23","author":"Gentile","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.029_bib25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.06.029_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-0716-1835-6_10","article-title":"Membrane and nuclear yeast two-hybrid systems","volume":"2400","author":"Chen","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2025.06.029_bib27","doi-asserted-by":"crossref","first-page":"17412","DOI":"10.1073\/pnas.1110271109","article-title":"Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system","volume":"109","author":"Lin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.029_bib28","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3389\/fmicb.2020.01252","article-title":"Identification of a compound that inhibits the growth of gram-negative bacteria by blocking BamA\u2013BamD interaction","volume":"11","author":"Li","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.029_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1213806","article-title":"Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant","volume":"13","author":"Wen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.apsb.2025.06.029_bib30","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study","volume":"1","author":"Chu","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.apsb.2025.06.029_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/v11010056","article-title":"Potent MERS-CoV fusion inhibitory peptides identified from HR2 domain in spike protein of bat coronavirus HKU4","volume":"11","author":"Xia","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.029_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01245-22","article-title":"Sertraline is an effective SARS-CoV-2 entry inhibitor targeting the spike protein","volume":"96","author":"Chen","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2025.06.029_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/v14030597","article-title":"A five-helix-based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern","volume":"14","author":"Xing","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.029_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2025.06.029_bib35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2025.06.029_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1995","journal-title":"Protein Eng"},{"key":"10.1016\/j.apsb.2025.06.029_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.06.029_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820806","article-title":"A comprehensive review on the therapeutic potential of curcuma longa linn. in relation to its major active constituent curcumin","volume":"13","author":"Fuloria","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2025.06.029_bib39","first-page":"2","article-title":"Drug like potential of daidzein using SwissADME prediction: in silico approaches","volume":"2","author":"Sardar","year":"2023","journal-title":"PHYTONutrients"},{"key":"10.1016\/j.apsb.2025.06.029_bib40","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.06.029_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005983","article-title":"Potent and broad inhibition of HIV-1 by a peptide from the gp41 heptad repeat-2 domain conjugated to the CXCR4 amino terminus","volume":"12","author":"Leslie","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2025.06.029_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2025.06.029_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41421-022-00419-w","article-title":"Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies","volume":"8","author":"Zhao","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.apsb.2025.06.029_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213253","article-title":"Inducing cathepsin L expression\/production, lysosomal activation, and autophagy of human dental pulp cells by dentin bonding agents, camphorquinone and BisGMA and the related mechanisms","volume":"145","author":"Chang","year":"2023","journal-title":"Biomater Adv"},{"key":"10.1016\/j.apsb.2025.06.029_bib45","doi-asserted-by":"crossref","first-page":"evad035","DOI":"10.1093\/gbe\/evad035","article-title":"Systematic exploration of SARS-CoV-2 adaptation to Vero E6, Vero E6\/TMPRSS2, and Calu-3 cells","volume":"15","author":"Aiewsakun","year":"2023","journal-title":"Genome Biol Evol"},{"key":"10.1016\/j.apsb.2025.06.029_bib46","doi-asserted-by":"crossref","first-page":"12262","DOI":"10.1073\/pnas.1608147113","article-title":"Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism","volume":"113","author":"Park","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.029_bib47","first-page":"382","article-title":"Progress in computational methods for the prediction of ADMET properties","volume":"5","author":"Clark","year":"2002","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1016\/j.apsb.2025.06.029_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1359-6446(03)02739-9","article-title":"Computational approaches to the understanding of ADMET properties and problems","volume":"8","author":"Modi","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.06.029_bib49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: towards prediction paradise?.","volume":"2","author":"Van De Waterbeemd","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.06.029_bib50","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/ci200387c","article-title":"Revisiting the general solubility equation: in silico prediction of aqueous solubility incorporating the effect of topographical polar surface area","volume":"52","author":"Ali","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2025.06.029_bib51","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200342060-00002","article-title":"Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges","volume":"42","author":"Masimirembwa","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.apsb.2025.06.029_bib52","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1359-6446(03)02649-7","article-title":"Pharmaceutical profiling in drug discovery","volume":"8","author":"Kerns","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.06.029_bib53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2025.06.029_bib54","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.06.029_bib55","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.06.029_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.06.029_bib57","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.2174\/138161210794079218","article-title":"Inhibition of HIV-1 by fusion inhibitors","volume":"16","author":"Eggink","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2025.06.029_bib58","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.06.029_bib59","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/jcb.21790","article-title":"Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors","volume":"104","author":"Chu","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2025.06.029_bib60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2008.10.001","article-title":"Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors","volume":"81","author":"Liu","year":"2009","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2025.06.029_bib61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.virusres.2006.03.001","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein","volume":"120","author":"Sainz","year":"2006","journal-title":"Virus Res"},{"key":"10.1016\/j.apsb.2025.06.029_bib62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-59259-948-6_18","article-title":"Development of a yeast two-hybrid screen for selection of human Ras\u2013Raf protein interaction inhibitors","volume":"310","author":"Khazak","year":"2005","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2025.06.029_bib63","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.apsb.2018.07.006","article-title":"Identification of anti-gram-negative bacteria agents targeting the interaction between ribosomal proteins L12 and L10","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.029_bib64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41392-023-01472-x","article-title":"Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2025.06.029_bib65","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0400576101","article-title":"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides","volume":"101","author":"Bosch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.029_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.addr.2020.11.007","article-title":"Peptide and peptide-based inhibitors of SARS-CoV-2 entry","volume":"167","author":"Schutz","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.06.029_bib67","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1021\/acs.jmedchem.1c00258","article-title":"Supercoiling structure-based design of a trimeric coiled-coil peptide with high potency against HIV-1 and Human beta-coronavirus infection","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.029_bib68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2174\/0929866525666180821122240","article-title":"An overview of current methods to confirm protein\u2013protein interactions","volume":"25","author":"Miura","year":"2018","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.apsb.2025.06.029_bib69","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2174\/1389201024666230330083640","article-title":"Isopeptide bond bundling superhelix for designing antivirals against enveloped viruses with class I fusion proteins: a review","volume":"24","author":"Na","year":"2023","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.apsb.2025.06.029_bib70","article-title":"Peptide-based inhibitors for SARS-CoV-2 and SARS-CoV","volume":"4","author":"Panchal","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2025.06.029_bib71","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.apsb.2021.07.026","article-title":"A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.029_bib72","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.abq3773","article-title":"Broadly neutralizing antibodies target the coronavirus fusion peptide","volume":"377","author":"Dacon","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.06.029_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2023.02.005","article-title":"Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease","volume":"56","author":"Zhou","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.06.029_bib74","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41423-021-00778-6","article-title":"A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development","volume":"18","author":"Li","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2025.06.029_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2022.06.004","article-title":"Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability","volume":"30","author":"Shi","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2025.06.029_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29145","article-title":"Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein","volume":"95","author":"Jiao","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2025.06.029_bib77","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/ijms26020678","article-title":"Establishment of a yeast two-hybrid-based high-throughput screening model for selection of SARS-CoV-2 spike-ACE2 interaction inhibitors","volume":"26","author":"Li","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.029_bib78","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/v14030489","article-title":"The analogs of furanyl methylidene rhodanine exhibit broad-spectrum inhibitory and inactivating activities against enveloped viruses, including SARS-CoV-2 and its variants","volume":"14","author":"Pu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.029_bib79","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-020-00325-1","article-title":"Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2025.06.029_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.virol.2021.01.015","article-title":"Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion","volume":"556","author":"Mondal","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.apsb.2025.06.029_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgac198","article-title":"Targeting an evolutionarily conserved \u201cE-L-L\u201d motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2","volume":"1","author":"Jana","year":"2022","journal-title":"PNAS Nexus"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352500454X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352500454X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:56:33Z","timestamp":1778846193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138352500454X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S221138352500454X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.06.029","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yeast-two-hybrid based high-throughput screening to discover SARS-CoV-2 fusion inhibitors by targeting the HR1\/HR2 interaction","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}